These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 16549967

  • 1. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection.
    Powers AE, Marden SF, McConnell R, Leidy NK, Campbell CM, Soeken KL, Barker C, Davey RT, Dybul MR.
    AIDS; 2006 Apr 04; 20(6):837-45. PubMed ID: 16549967
    [Abstract] [Full Text] [Related]

  • 2. Health-related quality of life in French people living with HIV in 2003: results from the national ANRS-EN12-VESPA Study.
    Préau M, Marcellin F, Carrieri MP, Lert F, Obadia Y, Spire B, VESPA Study Group.
    AIDS; 2007 Jan 04; 21 Suppl 1():S19-27. PubMed ID: 17159583
    [Abstract] [Full Text] [Related]

  • 3. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.
    Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS.
    J Infect Dis; 2003 Aug 01; 188(3):388-96. PubMed ID: 12870120
    [Abstract] [Full Text] [Related]

  • 4. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era.
    Saunders DS, Burgoyne RW.
    Int J STD AIDS; 2002 Oct 01; 13(10):683-90. PubMed ID: 12396538
    [Abstract] [Full Text] [Related]

  • 5. Intermittent antiretroviral therapy in patients with controlled HIV infection.
    Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, May T, Ragnaud JM, Aboulker JP, Molina JM, ANRS 106 Study team.
    AIDS; 2007 Feb 19; 21(4):457-66. PubMed ID: 17301564
    [Abstract] [Full Text] [Related]

  • 6. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A, Martinez E, Milinkovic A, Mora B, Mallolas J, Blanco JL, Larrousse M, Laguno M, Gallart T, Plana M, Gatell JM, Garcia F.
    J Antimicrob Chemother; 2009 Jan 19; 63(1):184-8. PubMed ID: 19001447
    [Abstract] [Full Text] [Related]

  • 7. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de Wolf F, Nieuwkerk PT.
    Clin Infect Dis; 2010 Jan 15; 50(2):255-63. PubMed ID: 20014949
    [Abstract] [Full Text] [Related]

  • 8. Health-related quality of life and health locus of control beliefs among HIV-infected treated patients.
    Préau M, Vincent E, Spire B, Reliquet V, Fournier I, Michelet C, Leport C, Morin M, APROCO study group.
    J Psychosom Res; 2005 Dec 15; 59(6):407-13. PubMed ID: 16310023
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR, Pediatric AIDS Clinical Trials Group 219/219C Study Team.
    Clin Infect Dis; 2008 Feb 15; 46(4):507-15. PubMed ID: 18199042
    [Abstract] [Full Text] [Related]

  • 13. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B, TIBET Study Group.
    AIDS; 2007 Jan 11; 21(2):169-78. PubMed ID: 17197807
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Health related quality of life among both current and former injection drug users who are HIV-infected.
    Préau M, Protopopescu C, Spire B, Sobel A, Dellamonica P, Moatti JP, Carrieri MP, MANIF-2000 Study Group.
    Drug Alcohol Depend; 2007 Jan 12; 86(2-3):175-82. PubMed ID: 16930864
    [Abstract] [Full Text] [Related]

  • 17. Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study.
    Grijsen M, Koster G, van Vonderen M, van Kasteren M, Kootstra G, Steingrover R, de Wolf F, Prins J, Nieuwkerk P, Primo-SHM study group.
    HIV Med; 2012 Nov 12; 13(10):630-5. PubMed ID: 22533544
    [Abstract] [Full Text] [Related]

  • 18. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
    Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, Viard JP, Weiss L, Netzer E, Delfraissy JF, Aboulker JP, Lévy Y.
    AIDS; 2007 Sep 12; 21(14):1887-97. PubMed ID: 17721096
    [Abstract] [Full Text] [Related]

  • 19. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
    Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM.
    Clin Infect Dis; 2007 Dec 15; 45(12):1633-9. PubMed ID: 18190326
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.